BlackRock Fund Advisors’s Utah Medical Products UTMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$7.99M Buy
109,767
+14,064
+15% +$914K ﹤0.01% 2696
2016
Q3
$5.72M Buy
95,703
+6,534
+7% +$416K ﹤0.01% 2784
2016
Q2
$5.62M Sell
89,169
-9,836
-10% -$634K ﹤0.01% 2725
2016
Q1
$6.19M Sell
99,005
-1,736
-2% -$102K ﹤0.01% 2629
2015
Q4
$5.9M Buy
100,741
+2,382
+2% +$135K ﹤0.01% 2746
2015
Q3
$5.3M Sell
98,359
-1,207
-1% -$65.8K ﹤0.01% 2773
2015
Q2
$5.94M Sell
99,566
-4,976
-5% -$280K ﹤0.01% 2825
2015
Q1
$6.26M Sell
104,542
-214
-0.2% -$12.6K ﹤0.01% 2717
2014
Q4
$6.29M Buy
104,756
+16,035
+18% +$888K ﹤0.01% 2737
2014
Q3
$4.33M Sell
88,721
-3,814
-4% -$194K ﹤0.01% 2836
2014
Q2
$4.76M Sell
92,535
-444
-0.5% -$22.8K ﹤0.01% 2868
2014
Q1
$5.38M Buy
92,979
+3,441
+4% +$188K ﹤0.01% 2783
2013
Q4
$5.12M Sell
89,538
-3,906
-4% -$214K ﹤0.01% 2814
2013
Q3
$5.55M Buy
93,444
+10,935
+13% +$597K ﹤0.01% 2737
2013
Q2
$4.48M Buy
+82,509
New +$3.88M ﹤0.01% 2763

Other funds holding UTMD

BlackRock Fund Advisors's UTMD Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Utah Medical Products (UTMD) stake by 15% in Q4 2016, buying an estimated $914K and bringing the position to 109,767 shares worth $7.99M. The position accounts for ﹤0.01% of the portfolio, ranked #2696.

BlackRock Fund Advisors first reported a position in UTMD in Q2 2013 and has held it in 15 quarters since. 75 funds tracked by Wall St. Rank hold UTMD as of Q4 2016.

  • BlackRock Fund Advisors held 109,767 shares of Utah Medical Products worth $7.99M as of Q4 2016.
  • BlackRock Fund Advisors bought 14,064 Utah Medical Products shares in Q4 2016, an estimated $914K.
  • Utah Medical Products made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2696 holding.
  • BlackRock Fund Advisors first reported a position in Utah Medical Products in Q2 2013 and has held it in 15 quarters since.
  • 75 funds tracked by Wall St. Rank held Utah Medical Products as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.